PMID: 9428950Jan 16, 1998Paper

Donepezil: an anticholinesterase inhibitor for Alzheimer's disease

American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
E Y Shintani, K M Uchida

Abstract

The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and dosage and administration of donepezil are reviewed. Donepezil is a synthetic noncovalent reversible inhibitor of acetylcholinesterase (AChE) for the treatment of mild to moderate dementia associated with Alzheimer's disease. In contrast to tacrine hydrochloride, the only comparable agent currently approved by FDA, donepezil exhibits a relatively high degree of selectivity for neuronal AChE as opposed to butyrylcholinesterase. It has a half-life of 60 hours in young adults and 104 hours in elderly patients. In clinical trials, donepezil has been associated with significant improvements in Alzheimer's Disease Assessment Scale-cognitive subscale and Clinical Interview-Based Impression of Change scores. The most common adverse effects associated with donepezil are nausea, diarrhea, anorexia, and vomiting, which are most likely to occur during dose initiation or adjustment. Hepatotoxicity, a dose-limiting adverse effect that sometimes requires discontinuation of tacrine, has not been reported with donepezil. Donepezil does not appear to interact with theophylline, cimetidine, warfarin, or digoxin. Ketoconazole and quinidine inhibit the me...Continue Reading

Citations

Nov 30, 2000·Current Treatment Options in Neurology·A S Schachter, K L Davis
Aug 7, 2002·Clinical Pharmacokinetics·Michael W JannGary W Small
Apr 28, 2005·Expert Review of Neurotherapeutics·David S Geldmacher
Oct 18, 2007·Expert Review of Neurotherapeutics·Boben Benjamin, Alistair Burns
Feb 4, 2009·Acta Clinica Belgica·R I R Dierckx, M F J Vandewoude
Jun 29, 2013·Journal of Biomolecular Structure & Dynamics·Flávio Roberto PinsettaCarlos Henrique Tomich de Paula da Silva
Sep 3, 2016·American Journal of Alzheimer's Disease and Other Dementias·Ahmet Turan IsikCansu Usarel
Aug 3, 2005·Drugs & Aging·Philippe BordierAlexia Lafitte
Dec 29, 2000·Journal of the American Geriatrics Society·M M VerricoA L Towers
Aug 31, 1999·The Annals of Pharmacotherapy·G ShepherdR Edwards
May 10, 2000·Drugs & Aging·M Dooley, H M Lamb
Apr 28, 2005·Expert Review of Neurotherapeutics·Christopher M Young, Robert L Findling
Jul 26, 2006·Expert Opinion on Drug Metabolism & Toxicology·Ben Seltzer
May 11, 2012·American Journal of Alzheimer's Disease and Other Dementias·Ahmet Turan IsikUmit Ateskan
Apr 15, 2014·Circulation Journal : Official Journal of the Japanese Circulation Society·Shuji ShimizuMasaru Sugimachi
Mar 2, 2019·Current Alzheimer Research·Eva MezeiovaJan Korabecny
Mar 28, 2012·Internal Medicine·Ahmet Turan IsikEmine Aydemir
Nov 28, 2018·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Tahir MuhammadMyeong Ok Kim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.

Related Papers

Drugs & Aging
H M Bryson, P Benfield
Drugs & Aging
David R Goldsmith, Lesley J Scott
Drug Safety : an International Journal of Medical Toxicology and Drug Experience
A Nordberg, A L Svensson
American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
M W Jann
© 2021 Meta ULC. All rights reserved